| 1.88 -0.015 (-0.79%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.28 |
1-year : | 2.53 |
| Resists | First : | 1.95 |
Second : | 2.17 |
| Pivot price | 1.87  |
|||
| Supports | First : | 1.61 |
Second : | 1.33 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 1.84 |
| MA(100) : | 1.56 |
MA(250) : | 1.61 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.7 |
D(3) : | 39.1 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 2.93 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MIST ] has closed below upper band by 49.5%. Bollinger Bands are 25.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.9 - 1.91 | 1.91 - 1.92 |
| Low: | 1.84 - 1.85 | 1.85 - 1.86 |
| Close: | 1.86 - 1.88 | 1.88 - 1.89 |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Wed, 20 Nov 2024
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright - MSN
Tue, 19 Nov 2024
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright - Yahoo Finance
Tue, 12 Nov 2024
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Tue, 12 Nov 2024
Milestone Pharmaceuticals: Q3 Earnings Snapshot - Barchart
Tue, 12 Nov 2024
Milestone Pharmaceuticals: Q3 Earnings Snapshot - San Antonio Express-News
Wed, 06 Nov 2024
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 57 (%) |
| Shares Short | 455 (K) |
| Shares Short P.Month | 437 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.1 % |
| Return on Equity (ttm) | -133.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -2.35 |
| PEG Ratio | 0 |
| Price to Book value | 4.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|